Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients With Chronic Inducible Urticaria
Celldex宣佈完成巴佐沃利單抗治療慢性誘發性蕁麻疹患者的2期研究的入組
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients With Chronic Inducible Urticaria
Celldex宣佈完成巴佐沃利單抗治療慢性誘發性蕁麻疹患者的2期研究的入組
使用瀏覽器的分享功能,分享給你的好友吧